---
title: "Understanding the Market | GIANT BIOGENE falls over 3% again, down more than 20% from historical highs, controversy over the ingredients of its KefuMei products continues to escalate"
description: "GIANT BIOGENE's stock price fell over 3% again, retreating more than 20% from its historical high, currently reported at HKD 65.9, with a trading volume of HKD 982 million. The controversy over the in"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242875422.md"
published_at: "2025-06-03T07:05:03.000Z"
---

# Understanding the Market | GIANT BIOGENE falls over 3% again, down more than 20% from historical highs, controversy over the ingredients of its KefuMei products continues to escalate

> GIANT BIOGENE's stock price fell over 3% again, retreating more than 20% from its historical high, currently reported at HKD 65.9, with a trading volume of HKD 982 million. The controversy over the ingredients of its product KefuMei continues to escalate, with a statement released on June 1 apologizing to the testing agency and stating that they will pursue legal responsibility for the rumor-mongers. Huaxi Biology expressed opposition to the name game regarding this controversy, emphasizing product quality issues. Morgan Stanley pointed out that GIANT BIOGENE will release more evidence from independent institutions to clarify consumer concerns

According to Zhitong Finance APP, GIANT BIOGENE (02367) has fallen over 3% again, with the current stock price down more than 20% from its historical high. As of the time of writing, it has dropped 3.44%, trading at HKD 65.9, with a transaction volume of HKD 982 million.

On the news front, the controversy surrounding the ingredients of GIANT BIOGENE's product KefuMei continues to escalate. On the evening of June 1, GIANT BIOGENE's WeChat official account released a statement titled "GIANT accepts the apology from the testing agency used by 'Big Mouth Doctor' (Hao Yu), but will pursue legal responsibility for the rumor-mongers." The statement mentioned that regarding the controversy over "KefuMei" not containing recombinant collagen, on May 30, the company received an apology statement from the testing agency used by "Big Mouth Doctor" (Hao Yu), which clearly stated, "Our company not only does not agree with this practice but has never granted any form of authorization," and strictly demanded that "Big Mouth Doctor" (Hao Yu) "immediately cease the use and forwarding of the 'Test Report' to avoid causing more serious misguidance to the public."

Additionally, according to the latest reports, Huaxi Bio responded on June 3 regarding the controversy over recombinant collagen with GIANT BIOGENE, stating that it opposes the name games like "recombinant" collagen, not the scientific research and industrial transformation of collagen itself. The company places more importance on the interaction between HA and collagen in ECM and pointed out that the credibility of domestic brands should not be built on the abuse of concepts, hoping the industry can return to product quality issues and seek solutions. Morgan Stanley recently pointed out that GIANT BIOGENE will release more evidence and test results conducted by independent agencies to clarify consumer concerns

### Related Stocks

- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)
- [688363.CN - Bloomage Biotech](https://longbridge.com/en/quote/688363.CN.md)
- [MS.US - Morgan Stanley](https://longbridge.com/en/quote/MS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜巨子生物多头信心松动，关键支撑岌岌可危？ | 1 月 27 日，巨子生物（2367.HK）盘中弱势震荡，盘面反复探底，多次试探 28 元整数关口支撑未果。全天资金持续流出，绿盘成交占比高，显示多头信心逐步松动，主力持仓筹码开始松懈。 生物科技板块过去一周受地方政策分歧影响，持续表现低迷 | [Link](https://longbridge.com/en/news/273815223.md) |
| 巨子生物获得中国批准推出全球首个胶原蛋白 - 透明质酸皮肤植入物 | 巨子生物控股有限公司已获得中国对其重组 I 型α1 亚型胶原蛋白和透明质酸复合溶液的批准，这是首个用于改善面颊光滑度的皮内注射产品。该产品增强了公司的胶原蛋白产品组合，并预计将为皮肤再生创造新的市场机会。目前，分析师对巨子生物股票（HK:2 | [Link](https://longbridge.com/en/news/272675579.md) |
| 华尔街大佬 Tepper 押注 AI：美光持仓激增 200%，新买韩国 ETF | 对冲基金大佬 Tepper 去年四季度精准狙击 AI 芯片赛道，豪掷逾 6 亿美元重仓美光科技和韩国芯片 ETF，今年已斩获约 30% 回报。全球内存短缺叠加 AI 算力狂潮，其芯片押注与软件股暴跌形成冰火两重天。 | [Link](https://longbridge.com/en/news/276213747.md) |
| 美股的 “危险信号” | 本月标普 500 指数成分股在八个交易日内下跌 7% 或以上的股票数量已经超过 100 只，直逼 2022 年美股熊市的水平。 虽然这不像新冠疫情或关税危机期间那样极端，但该指标超过 100 通常意味着更大范围的下滑，而这种情况目前还没有发 | [Link](https://longbridge.com/en/news/276185288.md) |
| 特朗普阵营的坚定降息派动摇了？美联储理事米兰：劳动力市场改善可令今年少些降息 | 坚定降息派、特朗普亲信美联储理事米兰：美国劳动力市场的改善可以令今年少些降息。风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符 | [Link](https://longbridge.com/en/news/276386713.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.